Telegraph.co.uk |
Blood test could pick up early signs of Alzheimer's disease 10 years early
Telegraph.co.uk Dr Eric Karran, Director of Research at Alzheimer's Research UK, the UK's leading dementia research charity said: “Accurate and early diagnosis of Alzheimer's will be essential for the development of new treatments, allowing clinical trials to take … Alzheimer's breakthrough: New blood test 'could predict risk up to 10 years … The other dementia: vascular most common after Alzheimer's Paula to lead the way in charity cycle challenge |
The other dementia: vascular most common after Alzheimer’s – Wichita Eagle
Wichita Eagle |
The other dementia: vascular most common after Alzheimer's
Wichita Eagle About 30 years ago, it was believed that people with dementia all had cerebral vascular disease and strokes. We now know that several diseases other than Alzheimer's disease cause significant cognitive impairment. There are similarities of these … Alzheimer's breakthrough: New blood test 'could predict risk up to 10 years … Blood test could pick up early signs of Alzheimer's disease 10 years early Paula to lead the way in charity cycle challenge |
Research explores screening methods, clinical care for patients with Alzheimer … – News-Medical.net
News-Medical.net |
Research explores screening methods, clinical care for patients with Alzheimer …
News-Medical.net Every 67 seconds someone is the United States develops Alzheimer's disease or some form of dementia. It's the sixth leading cause of death in the U.S. and it's the only cause of death in the top 10 in America that cannot be prevented, cured or slowed. |
Disclosing a Dementia Diagnosis: Why So Important? – Medscape
|
Disclosing a Dementia Diagnosis: Why So Important?
Medscape According to the Alzheimer's Association, fewer than half of people with Alzheimer disease (AD) or their caregivers have been told of their diagnosis by their healthcare provider. There are likely several reasons for this, but an important factor for … |
St. Mary’s signing up volunteers for Alzheimer’s-dementia study – Enid News & Eagle
Enid News & Eagle |
St. Mary's signing up volunteers for Alzheimer's–dementia study
Enid News & Eagle Studies range from medication and prescription trials to behavioral research, all aimed at better understanding Alzheimer's and dementia, as well as developing treatment and a cure. If volunteers choose not to or are not able to participate in the … |
What is dementia? – Toronto Sun
Toronto Sun |
What is dementia?
Toronto Sun Mimi Low-Young, CEO of the Alzheimer Society of Canada, said dementia symptoms don't just include short-term memory loss but sudden changes in mood, putting things in the wrong place, repeating words, showing poor judgment, not being aware of your … 25th annual Alzheimer's walk Chief Executive of Alzheimer's Society awarded CBE in Queen's Birthday Honours Mon, Jun 15th, 2015 |
Lysosomal Proteins Higher with Dementia, Alzheimer’s – Neurology Advisor
Neurology Advisor |
Lysosomal Proteins Higher with Dementia, Alzheimer's
Neurology Advisor HealthDay News — Lysosomal proteins may offer a way to diagnose and treat Alzheimer's disease earlier, a new study suggests. The findings were published online June 10 in Neurology. Edward Goetzl, MD, professor of medicine with the University of … Early neuronal lysosomal dysfunction could help predict AD |
Dementia drug developer Axovant climbs after $315M IPO – SFGate
|
Dementia drug developer Axovant climbs after $315M IPO
SFGate Axovant is preparing to start late-stage trials of RVT-101 as a once-per-day treatment for dementia caused by Alzheimer's disease and also wants to study the drug as a treatment for other types of dementia. British drugmaker GlaxoSmithKline PLC … |
More African Americans at risk for dementia – WRCB-TV
WRCB-TV |
More African Americans at risk for dementia
WRCB-TV When it comes to dementia and Alzheimer's ,many Americans dismiss the warning signs, believing the symptoms are a normal part of aging. This is of even greater concern in the African-American community. Cola Harris, wife of Alzheimer's patient says … |
Dementia Drug Developer Axovant Climbs After $315M IPO – ABC News
ValueWalk |
Dementia Drug Developer Axovant Climbs After $315M IPO
ABC News The company is preparing to start late-stage trials of RVT-101 as a once-per-day treatment for dementia caused by Alzheimer's disease and also wants to study it as a treatment for other types of dementia. Axovant says that in one clinical study … Did Glaxo's scientists miss a blockbuster Alzheimer's drug? |